Hillrom to Acquire Bardy Diagnostics for $375 Million
Chicago-based global medtech giant Hillrom has announced that it will purchase Seattle startup Bardy Diagnostics for $375 million.
Through the planned acquisition, Hillrom will obtain the BardyDx ambulatory cardiac- monitoring devices, including the Carnation Ambulatory Monitor, a lightweight patch worn along the sternum that collects information about a patient’s heart rhythm.
Hillrom said it expects to finalize the agreement in the second quarter of 2021. Under the terms of the acquisition, the price of the deal may increase if certain milestones are met by Bardy.